0001209191-21-062493.txt : 20211102 0001209191-21-062493.hdr.sgml : 20211102 20211102180845 ACCESSION NUMBER: 0001209191-21-062493 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211101 FILED AS OF DATE: 20211102 DATE AS OF CHANGE: 20211102 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Shams Soheil CENTRAL INDEX KEY: 0001888376 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38613 FILM NUMBER: 211372839 MAIL ADDRESS: STREET 1: C/O BIONANO GENOMICS, INC. STREET 2: 9540 TOWNE CENTRE DRIVE, SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Bionano Genomics, Inc. CENTRAL INDEX KEY: 0001411690 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 261756290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9540 TOWNE CENTRE DRIVE STREET 2: SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 888-7600 MAIL ADDRESS: STREET 1: 9540 TOWNE CENTRE DRIVE STREET 2: SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: Bionano Genomics, Inc DATE OF NAME CHANGE: 20190308 FORMER COMPANY: FORMER CONFORMED NAME: BioNano Genomics, Inc DATE OF NAME CHANGE: 20120703 FORMER COMPANY: FORMER CONFORMED NAME: BioNanomatrix Inc DATE OF NAME CHANGE: 20070906 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-11-01 0 0001411690 Bionano Genomics, Inc. BNGO 0001888376 Shams Soheil C/O BIONANO GENOMICS, INC. 9540 TOWNE CENTRE DRIVE, SUITE 100 SAN DIEGO CA 92121 0 1 0 0 Chief Informatics Officer Stock Option (Right to Buy) 5.40 2021-11-01 4 A 0 400000 0.00 A 2031-11-01 Common Stock 400000 400000 D 25% of the shares subject to the option shall vest and become exercisable on October 18, 2022, and the remaining shares shall vest in a series of 36 successive equal monthly installments measured from October 18, 2022, subject to Reporting Person's Continuous Service (as defined in the Company's 2020 Inducement Plan) through each such applicable vesting date and the terms of the Company's 2020 Inducement Plan. /s/ R. Erik Holmlin, Attorney-in-Fact 2021-11-02